Vanguard Group Inc Eye Point Pharmaceuticals, Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,834,368 shares of EYPT stock, worth $27.8 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,834,368
Previous 3,803,227
0.82%
Holding current value
$27.8 Million
Previous $28.3 Million
26.65%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding EYPT
# of Institutions
164Shares Held
71.6MCall Options Held
232KPut Options Held
207K-
Cormorant Asset Management, LP Boston, MA8.33MShares$60.3 Million4.79% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.8MShares$49.3 Million1.61% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.2MShares$44.9 Million0.07% of portfolio
-
Franklin Resources Inc San Mateo, CA4.15MShares$30 Million0.01% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA4.09MShares$29.6 Million0.05% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $247M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...